CD23 (FCE2) is a type II integral membrane glycoprotein that is expressed on mature B cells, monocytes, eosinophils, platelets and dendritic cells. CD23 is a low affinity IgE receptor that mediates IgE-dependent cytotoxicity and phagocytosis by macrophages and eosinophils. CD23 associates as an oligomer where cooperative binding of at least two lectin domains is required for high affinity IgE binding to CD23. It may play a role in antigen presentation by B cells by interacting with CD40. CD23 has been shown to be associated with the Fyn tyrosine kinase. The truncated molecule can be secreted, then function as a potent mitogenic growth factor. CD23 is expressed on a subpopulation of peripheral blood cells, B-lymphocytes and on EBV transformed B lymphoblastoid cell lines. CD23 is also detected in neoplastic cells from cases of B cell chronic lymphocytic leukemia and some cases on centroblastic/centrocytic lymphoma.
Applications
IHC-P
Dilutions
IHC-P: 1-2 µg/ml
Reactivity
Human
Immunogen
Recombinant fragment, around amino acids 48-321, of human CD23 protein. The exact sequence is proprietary.
SDS-PAGE analysis of Anti-CD23 Antibody [FCER2/6890] under non-reduced and reduced conditions; showing intact IgG and intact heavy and light chains, respectively. SDS-PAGE analysis confirms the integrity and purity of the antibody.
Immunohistochemical analysis of formalin-fixed, paraffin-embedded human colon using Anti-CD23 Antibody [FCER2/6890] at 2µg/ml in PBS for 30 minutes at room temperature.
Negative Tissue Control: Immunohistochemical analysis of formalin-fixed, paraffin-embedded human brain using Anti-CD23 Antibody [FCER2/6890] at 2µg/ml in PBS for 30 minutes at room temperature.
Publishing research using Anti-CD23 Antibody [FCER2/6890] (A277597)? Please let us know so that we can list the citation on this page.
Alternative products to Anti-CD23 Antibody [FCER2/6890] (A277597)